Successful Treatment of Primary Sclerosing Cholangitis with a Steroid and a Probiotic by Shimizu, Masaki et al.
 
Case Rep Gastroenterol 2012;6:249–253 
DOI: 10.1159/000338834 
Published online: 
May 8, 2012 
© 2012 S. Karger AG, Basel 
ISSN 1662–0631 
www.karger.com/crg 
This is an Open Access article licensed under the terms of the Creative Commons 
Attribution-NonCommercial-NoDerivs 3.0 License (www.karger.com/OA-license), applicable 
to the online version of the article only. Distribution for non-commercial purposes only.   
 
                      Masaki Shimizu, MD, PhD    Department of Pediatrics, School of Medicine 
Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University 
13-1 Takaramachi, Kanazawa 920-8641 (Japan) 
Tel. +81 76 265 2314, E-Mail shimizum @ staff.kanazawa-u.ac.jp 
 
249 
   
Successful Treatment of 
Primary Sclerosing Cholangitis 
with a Steroid and a Probiotic 
Masaki Shimizu    Hidenori Iwasaki    Shintaro Mase    
Akihiro Yachie 
Department of Pediatrics, School of Medicine, Institute of Medical, 
Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan 
 
 
Key Words 
Primary sclerosing cholangitis · Inflammatory bowel disease · Probiotics 
 
 
Abstract 
Primary sclerosing cholangitis (PSC) is a serious disease that not only affects quality of life 
but can also have a significant effect on patient survival. The treatment for PSC is primarily 
supportive with the aim of controlling cholestatic symptoms and preventing complications. 
Ursodeoxycholic acid may induce biochemical improvements in affected patients; however, 
long-term pediatric studies to determine its possible benefits in young patients are lacking. 
Thus, the treatment of pediatric PSC remains a significant clinical challenge. We describe a 
patient with PSC and undetermined colitis who was treated with a combination of a steroid, 
salazosulfapyridine, and a probiotic. This treatment provided benefits both for PSC and the 
undetermined colitis. These findings suggest that bacterial flora and gut inflammation are 
closely associated with the pathogenesis of inflammatory bowel disease-related PSC. 
Suppression of bowel inflammation and maintenance of bacterial homeostasis may be 
important for treating PSC. 
 
Introduction 
Primary sclerosing cholangitis (PSC) is a chronic cholestatic liver disease 
characterized by inflammation and progressive obliterative fibrosis of the intrahepatic 
and/or extrahepatic bile ducts. There is a close association between PSC and 
inflammatory bowel disease (IBD) [1]. However, the pathogenesis of IBD-related PSC 
remains unknown. Increasing evidence suggests that immune mechanisms play a 
critical role in the pathogenesis of PSC [2], and it has been hypothesized that 
gut-homing lymphocytes may be the common denominator underlying both IBD and 
PSC [2].  
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A possible nonimmune mechanism involved in PSC pathogenesis is the release of 
toxic agents either by gut bacteria or following ischemic injury [3]. Interestingly, 
antibiotics have been used to treat PSC in several patient series over the years, and they 
exhibited benefits in some patients [3, 4]. These observations suggest that bacterial 
flora and gut inflammation might be closely associated with the pathogenesis of both 
IBD and PSC. 
PSC is a serious disease that not only affects quality of life but can also have a 
significant effect on patient survival. The treatment for PSC is primarily supportive 
with the aim of controlling cholestatic symptoms and preventing complications. 
Ursodeoxycholic acid (UDCA) may induce biochemical improvements in patients. 
However, long-term pediatric studies to determine its possible benefits in young 
patients are lacking. Thus, treating pediatric PSC remains a significant clinical 
challenge.  
In this report, we describe a patient with PSC and undetermined colitis who was 
successfully treated with a combination of a steroid, salazosulfapyridine, and a 
probiotic. 
Case Report 
A 13-year-old boy with a 4-week history of fever, abdominal pain and associated anemia and liver 
dysfunction was referred to us. His laboratory data on admission showed the following: aspartate 
aminotransferase 80 IU/l, alanine aminotransferase 102 IU/l, alkaline phosphatase 2,663 IU/l, 
γ-glutamyl transpeptidase 524 IU/l, immunoglobulin G 2,180 mg/dl, and erythrocyte sedimentation 
rate 111 mm/h (table 1). Colonoscopy revealed pancolitis including erosive lesions with rectal 
sparing, but without granulomatous changes. A diagnosis of undetermined colitis was made. 
Magnetic resonance cholangiopancreatography showed an irregular contour of the intrahepatic 
bile duct (fig. 1a). A liver biopsy revealed severe biliary tract outflow obstruction and chronic active 
inflammation involving the biliary ducts (fig. 1b, c). Findings of hepatocellular involvement consistent 
with autoimmune hepatitis were not significant. Endoscopic retrograde cholangiography showed 
narrowing and irregularities of the intrahepatic bile ducts. A diagnosis of PSC associated with 
undetermined colitis was made. 
Treatment with UDCA (600 mg/day) and mesalazine (2,000 mg/day) was started, after which his 
symptoms improved temporarily. However, he had fever and bloody diarrhea 2 weeks after initiating 
this treatment. Mesalazine was replaced with prednisolone (30 mg/day), salazosulfapyridine 
(3,000 mg/day) and a probiotic (Lactobacillus casei Shirota, 3 g/day). Two weeks later, the patient’s 
symptoms and laboratory results had improved (table 1). 
The prednisolone dose was gradually tapered off. A repeat biopsy at 30 months showed significant 
improvements in inflammatory cell infiltration and periductal fibrosis and a decrease in fibrotic areas 
from 10.5 to 3.6% in each specimen (fig. 1d). Three years later, the patient continues to take UDCA, 
salazosulfapyridine and probiotics. He is in complete remission. 
Discussion 
Immunosuppressive therapy with corticosteroids and/or azathioprine is often 
used in the treatment of IBD. These drugs have also been used for treating pediatric 
patients with PSC [5]. Children with autoimmune cholangitis should be expected 
to respond to immunosuppressive therapy when liver histology shows interface 
hepatitis, immunoglobulin G levels are elevated and autoimmune markers are present.  
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Antibiotics have been used to treat PSC and exhibited benefits in some cases [3, 4]. 
These findings suggest that bacterial flora and gut inflammation may be closely 
associated with the pathogenesis of both IBD and PSC.  
Probiotics are nonpathogenic viable microorganisms that have beneficial effects for 
host health, disease prevention and/or treatment. Clinical trials have shown some 
beneficial effects of probiotics in IBD [6]. The suggested mechanisms for probiotic 
regulation in IBD therapy are the following. First, probiotics block bacterial pathogenic 
effects by producing bactericidal substances and competing with pathogens and toxins 
for adherence to the intestinal epithelium. Second, probiotics regulate immune 
responses by enhancing innate immunity and modulating pathogen-induced 
inflammation via toll-like receptor-regulated signaling pathways. Third, probiotics 
regulate intestinal epithelial homeostasis by promoting intestinal epithelial cell 
survival, enhancing barrier function and stimulating protective responses. 
For our patient, the combination of immunosuppressive therapy and a probiotic 
provided benefits for both IBD and PSC, which suggests that bacterial flora and gut 
inflammation are closely associated with the pathogenesis of IBD-related PSC. 
Suppressing bowel inflammation and maintaining bacterial homeostasis in the gut is 
important in the treatment of PSC. The results of a randomized controlled trial showed 
that probiotics alone could not control symptoms or improve liver function in adult PSC 
patients [7]. However, additional studies are needed to determine the effects of 
probiotics as an adjunctive therapy in pediatric IBD-related PSC. 
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Table 1. Laboratory data on admission 
                  Onset  Two weeks  
after treatment 
<Normal 
                Aspartate aminotransferase, IU/l  80  14  <13–33 
Alanine aminotransferase, IU/l  102  13  <6–27 
Alkaline phosphatase, IU/l  2,663  372  <115–319 
Gamma-glutamyl transpeptidase, IU/l  524  16  <10–47 
Immunoglobulin G, mg/dl  2,180  1,570  <870–1,700 
Erythrocyte sedimentation rate, mm/h  111  10  <15 
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Fig. 1. Pathological findings in PSC. a Magnetic resonance cholangiopancreatography showed an 
irregular contour of the intrahepatic bile duct. b, c The first liver biopsy revealed severe changes, 
including biliary tract outflow obstruction and chronic active inflammation involving the biliary tree 
(Azan staining; original magnification: b ×400, c ×100). d The second biopsy showed significant 
improvements in inflammatory cell infiltration and periductal fibrosis. Fibrotic areas had decreased 
from 10.5 to 3.6% in each specimen (Azan staining; original magnification: ×100). 
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